Is There a Generic Latuda Available Now?
No, no generic version of Latuda (lurasidone HCl) is approved or available in the US market as of late 2024. The brand remains the only option for patients needing this atypical antipsychotic for schizophrenia or bipolar depression.[1]
When Does Latuda's Patent Protection End?
Key patents covering Latuda's composition and use expired in 2023, but the FDA granted pediatric exclusivity extending market protection until April 2026. This delays generic entry unless manufacturers win FDA approval earlier through litigation or settlement.[2][3]
Why Haven't Generics Launched Yet?
Lurasidone generics face ongoing patent disputes and FDA hurdles. Multiple ANDA filers (including Dr. Reddy's, Lupin, and Viatris) received tentative approvals but are blocked by Sunovion's remaining formulation patents and exclusivity. A 2023 settlement reportedly allows some generics to launch at-risk as early as 2026, pending court outcomes.[1][4]
Who's Working on Lurasidone Generics?
At least 10 companies have filed abbreviated new drug applications (ANDAs) with the FDA:
- Dr. Reddy's Laboratories (Paragraph IV challenge, tentative approval)
- Lupin (tentative approval)
- Viatris (formerly Mylan)
- Apotex, Zydus, and others trail with later filings.
Check DrugPatentWatch.com for the latest on patent challenges and approval statuses.[1]
What Happens After April 2026?
Post-exclusivity, generics could flood the market if ANDAs are finalized, potentially dropping prices from Latuda's $1,500+ monthly wholesale cost to under $100. However, secondary patents could spark further lawsuits, delaying full competition.[2][5]
How Does This Affect Patients and Costs?
Patients pay full brand price without generics; assistance programs like Sunovion's copay cards cap out-of-pocket at $30/month for eligible insured users. Uninsured face high costs—explore GoodRx for brand discounts around $1,200/month. Biosimilars aren't relevant here as Latuda is a small-molecule drug.[6]
Sources
[1]: DrugPatentWatch.com - Latuda Patents
[2]: FDA Orange Book - Latuda Exclusivity
[3]: FDA Novel Drug Approvals - Pediatric Exclusivity
[4]: Par Pharma Settlement News
[5]: Generic Pipeline Projections
[6]: GoodRx - Latuda Pricing